Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$771.89K$771.89K+154.6% vs Q3 2017 Net Income-$8.43M-$8.43MN/M vs Q3 2017 EPS Diluted-$0.26-$0.26N/M vs Q3 2017 Operating Income-$7,219,892N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,703,332N/M Margins · derivedOperating margin-935.4%+1484.8 pt vs Q3 2017
Net margin-1092.4%+666.3 pt vs Q3 2017
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end